Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial

1996 ◽  
Vol 3 (2) ◽  
pp. 110-117 ◽  
Author(s):  
Marc K. Wallack ◽  
Muthukumaran Sivanandham ◽  
Brian Whooley ◽  
Kristen Ditaranto ◽  
Alfred A. Bartolucci
Keyword(s):  
Vaccine Trial ◽  
Melanoma Vaccine ◽  
Clinical Responses

Favourable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial

1996 ◽  
Vol 22 (2) ◽  
pp. 204
Author(s):  
Marc K. Wallack ◽  
Muthukumaran Sivanandham ◽  
Brian Whooley ◽  
Kristen Ditaranto ◽  
Alfred A. Bartolucci
Keyword(s):  
Vaccine Trial ◽  
Melanoma Vaccine ◽  
Clinical Responses

Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial

2006 ◽  
Vol 16 (3) ◽  
pp. 1075-1081 ◽  
Author(s):  
A. N. Fiander ◽  
A. J. Tristram ◽  
E. J. Davidson ◽  
A. E. Tomlinson ◽  
S. Man ◽  
...  
Keyword(s):  
Phase Ii ◽  
Hpv Vaccination ◽  
Vaccine Trial ◽  
Vaccination Strategy ◽  
Intraepithelial Neoplasia ◽  
Clinical Effectiveness ◽  
Clinical Results ◽  
Hpv 16 ◽  
Boost Vaccination ◽  
Clinical Responses

The objective of this study was to determine the clinical effectiveness of a prime-boost human papillomavirus (HPV) vaccine regimen. A nonrandomized phase II prime-boost vaccine trial was conducted. Women with biopsy-proven anogenital intraepithelial neoplasia (AGIN) 3 were vaccinated with three doses of a recombinant fusion protein comprising HPV 16, E6/E7/L2 (TA-CIN) followed by one dose of a recombinant vaccinia virus encoding HPV 16 and 18 E6/E7 (TA-HPV). Clinical responses were evaluated by serial photographs, symptomatology, and biopsies before and after vaccination. Twenty-nine women were vaccinated; 27 with vulval intraepithelial neoplasia 3 and 2 with vaginal intraepithelial neoplasia grade 3. Clinical responses were seen in five women (17%), with one complete and five partial responses. Fifteen women (62%) had symptomatic improvement. No serious adverse effects were recorded. This is the first trial of a prime-boost vaccination regimen using heterologous HPV vaccines (TA-CIN followed by TA-HPV) in the management of AGIN. Since the prime-boost approach in this cohort offered no significant advantages over single TA-HPV vaccination, there are no further studies planned using this protocol. Future studies are warranted to define responders to immunotherapy.

scholarly journals Usefulness of prestudy assessment of patient willingness to undergo tissue biopsy for correlative studies in a melanoma vaccine trial

2012 ◽  
Vol 10 (1) ◽  
pp. 143-150 ◽  
Author(s):  
Joshua M Judge ◽  
Kimberly A Chianese-Bullock ◽  
Anneke T Schroen ◽  
Craig L Slingluff
Keyword(s):  
Vaccine Trial ◽  
Melanoma Vaccine ◽  
Tissue Biopsy ◽  
Correlative Studies ◽  
Patient Willingness

8 Analyses of a melanoma vaccine trial

2004 ◽  
Vol 14 (4) ◽  
pp. A5
Author(s):  
D. Berd ◽  
T. Sato ◽  
H. Maguire ◽  
M. Mastrangelo
Keyword(s):  
Vaccine Trial ◽  
Melanoma Vaccine

scholarly journals Multi-institutional melanoma vaccine trial

1996 ◽  
Vol 3 (6) ◽  
pp. 588-589 ◽  
Author(s):  
Vernon K. Sondak
Keyword(s):  
Vaccine Trial ◽  
Melanoma Vaccine

A leading coronavirus vaccine trial is on hold: scientists react

Nature ◽  
2020 ◽  
Author(s):  
Nicky Phillips ◽  
David Cyranoski ◽  
Smriti Mallapaty
Keyword(s):  
Vaccine Trial

Scientists relieved as coronavirus vaccine trial restarts — but question lack of transparency

Nature ◽  
2020 ◽  
Vol 585 (7825) ◽  
pp. 331-332 ◽  
Author(s):  
David Cyranoski ◽  
Smriti Mallapaty
Keyword(s):  
Vaccine Trial
Sign in / Sign up

Export Citation Format

Share Document